$599

DELIVER Delivers for AZ; Priority Review Depends on CV Death

AstraZeneca announced top-line results from the Ph3 DELIVER trial (view CT.gov record) demonstrating AZ’s Farxiga (dapagliflozin) has met the primary composite endpoint of CV death or worsening HF in HFpEF subjects. Below, FENIX provides initial thoughts.

This content is for Read Less members only.
Register
Already a member? Log in here